Showing results (31-40 of 77) with videos related to

Sort By:
Pageof 8
Cellular & Molecular Biology Letters|July 30, 2013
The NTPase/helicase domain of hepatitis C virus nonstructural protein 3 inhibits protein kinase C independently of its NTPase activityPhilip Hartjen, Bastian Höchst, Denise Heim, et al.
Gastroenterology|January 31, 2003
Telomerase reconstitution immortalizes human fetal hepatocytes without disrupting their differentiation potentialHenning Wege, Hai T Le, Michael S Chui, et al.
Journal of Hepatology|September 17, 2024
Rare primary liver cancers: An EASL position paperHenning Wege, Claudia Campani, Ruben de Kleine, et al.
Plos One|December 23, 2021
Low incidence of COVID-19 in a prospective cohort of patients with liver cirrhosis and hepatocellular carcinoma treated at a tertiary medical center during the 2020 pandemicThorben Fründt, Lilith Kuballa, Marc Lütgehetman, et al.
Advances in Therapy|September 16, 2025
Tiprelestat for treatment of hospitalized COVID-19: results of the double-blind randomized placebo-controlled COMCOVID trialIngmar Bergs, Stephan Budweiser, Hans-Heinrich Henneicke-von Zepelin, et al.
Cancers|February 15, 2022
Equal Efficacy and Safety Profile in Elderly Patients with Hepatocellular Carcinoma Receiving Palliative TreatmentThorben W Fründt, Christian Casar, Johann von Felden, et al.
BMC Cancer|August 1, 2015
Adjuvant chemotherapy with gemcitabine and cisplatin compared to observation after curative intent resection of cholangiocarcinoma and muscle invasive gallbladder carcinoma (ACTICCA-1 trial) - a randomized, multidisciplinary, multinational phase III trialAlexander Stein, Dirk Arnold, John Bridgewater, et al.
Experimental Hematology|October 14, 2010
Functional p53 is required for effective execution of telomerase inhibition in BCR-ABL-positive CML cellsUte Brassat, Stefan Balabanov, Daniel Bali, et al.
BMC Cancer|August 1, 2024
Radiofrequency ablation via catheter and transpapillary access in patients with cholangiocarcinoma (ACTICCA-2 trial) - a multicenter, randomized, controlled, open-label investigator-initiated trialConstantin Schmidt, Antonia Zapf, Ann-Kathrin Ozga, et al.
Oncotarget|November 18, 2014
Specific genomic and transcriptomic aberrations in tumors induced by partial hepatectomy of a chronically inflamed murine liverEzra Ella, Denise Heim, Evgeniy Stoyanov, et al.
Pageof 8